Clinical trial
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft…
NCT00142571 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00142571 |
|---|---|
| Title | Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma |
| Official title | Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | Connective Tissue Oncology Society M.D. Anderson Cancer Center Massachusetts General Hospital Mayo Clinic University of Michigan Rogel Cancer Center |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sarcoma, Soft Tissue |
| Intervention type | Drug |
| Interventions | Gemcitabine, Docetaxel |
| Enrollment | 120 |
| Start date | Jan 1, 2003 |
| Completion | Sep 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Oct 2, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: